CSTL
Castle Biosciences Inc

1,010
Mkt Cap
$1.16B
Volume
33,343.00
52W High
$40.61
52W Low
$14.59
PE Ratio
-88.02
CSTL Fundamentals
Price
$39.01
Prev Close
$39.62
Open
$39.53
50D MA
$28.98
Beta
1.12
Avg. Volume
595,283.32
EPS (Annual)
$0.6236
P/B
2.47
Rev/Employee
$436,358.74
Loading...
Loading...
News
all
press releases
Universal Beteiligungs und Servicegesellschaft mbH Grows Stock Position in Castle Biosciences, Inc. $CSTL
Universal Beteiligungs und Servicegesellschaft mbH grew its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 364.6% during the second quarter, according to its most...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
Derek Maetzold Sells 5,115 Shares of Castle Biosciences (NASDAQ:CSTL) Stock
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 5,115 shares of the company's stock in a transaction that occurred on Tuesday, November 25th. The shares were sold...
MarketBeat·8d ago
News Placeholder
Castle Biosciences (NASDAQ:CSTL) Insider Sells $204,855.75 in Stock
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 5,115 shares of the firm's stock in a transaction on Tuesday, November 25th. The stock was sold at an average...
MarketBeat·8d ago
News Placeholder
Castle Biosciences (NASDAQ:CSTL) Hits New 52-Week High - Time to Buy?
Castle Biosciences (NASDAQ:CSTL) Hits New 12-Month High - Here's Why...
MarketBeat·8d ago
News Placeholder
Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 4,693 Shares
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Tobin Juvenal sold 4,693 shares of the stock in a transaction on Thursday, November 20th. The shares were sold at an average price of...
MarketBeat·10d ago
News Placeholder
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
Zacks·10d ago
News Placeholder
FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer
Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.
Zacks·11d ago
News Placeholder
Castle Biosciences (NASDAQ:CSTL) Sets New 1-Year High - Time to Buy?
Castle Biosciences (NASDAQ:CSTL) Hits New 1-Year High - Here's Why...
MarketBeat·14d ago
News Placeholder
Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable
Castle Biosciences (CSTL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zacks·14d ago
News Placeholder
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal
Alkermes lifts its bid to buy Avadel for $22.50 per share as its takeover fight with Lundbeck intensifies and shifts the deal's momentum.
Zacks·15d ago

Latest CSTL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.